<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925402</url>
  </required_header>
  <id_info>
    <org_study_id>AMED2019</org_study_id>
    <nct_id>NCT03925402</nct_id>
  </id_info>
  <brief_title>Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia</brief_title>
  <official_title>Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia: a Propensity Score Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess whether ertapenem as an empiric treatment of
      third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is
      non-inferior to other carbapenems in term of 30-day mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are limited data of the efficacy of ertapenem as the empiric treatment of serious
      invasive infections, such as bloodstream infections (BSIs), that are due to ESBL-producing
      Enterobacteriaceae. Previous studies of ertapenem were done in small group of patients, in
      less invasive infection, as a definite 'step-down' therapy, or as compared to other
      non-carbapenem antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>death from any cause within 30 days after the blood culture with bacteraemia is drawn</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>90 days</time_frame>
    <description>death from any cause within the duration of admission with bacteraemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14-day mortality</measure>
    <time_frame>14 days</time_frame>
    <description>death from any cause within 14 days after the blood culture with bacteraemia is drawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days</time_frame>
    <description>death from any cause within 90 days after the blood culture with bacteraemia is drawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ Length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of admission with bacteraemia</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Bacteremia</condition>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <description>Patients who received ertapenem as an empirical antibiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other carbapenems</arm_group_label>
    <description>Patients who received carbapenems other than ertapenem as an empirical antibiotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Ertapenem injection</description>
    <arm_group_label>Ertapenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbapenems</intervention_name>
    <description>Other carbapenems injection</description>
    <arm_group_label>Other carbapenems</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 years of age and older admitted to Phramongkutklao Hospital, and Ananda Mahidol
        Hospital with 3GCRE monomicrobial bacteremia will be prospectively identified. In given a
        patient, only the initial episode of 3GCRE monomicrobial bacteremia during the study period
        will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, either sex, ages 18 years or above

          -  Patients with 3GCRE bacteremia

          -  Patients admitted to any of the study sites

        Exclusion Criteria:

          -  Discontinuation of antibiotic due to transition to hospice care

          -  Polymicrobial bacteremia

          -  Empirical antibiotic after 24 hours of first evidence of bacteremia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vasin Vasikasin, MD</last_name>
    <phone>027633338</phone>
    <email>vvasin@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasin Vasikasin, MD</last_name>
      <email>vvasin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

